Overview

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII)) produced by two different manufacturers (Novo Nordisk and Avecia) in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S